Claude‐Eric Bulabois

Author

Centre Hospitalier Universitaire de Grenoble ORCID

Also Known As

B. Lioure, C E Bulabois, C. Bulabois, C. E. Bulabois, C.-E. Bulabois, C.E. Bulabois, C.‐E. Bulabois, CLAUDE-ERIC BULABOIS, Claude Bulabois, Claude E. Bulabois

177

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Grenoble Inserm Hôpital Saint-Louis Sorbonne Université Université Grenoble Alpes

About

Claude‐Eric Bulabois is an author at Centre Hospitalier Universitaire de Grenoble specializing in medicine, transplantation, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	794
2	Health Sciences	11	12	447
3	Blood Transplantation	10	10	418
4	Cellular Therapies	7	7	283
5	Cell Biology	1	1	13

Claude‐Eric Bulabois

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia Éric Jourdan, Nicolas Boissel, Sylvie Chevret, Blood	2013	350
Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire Steven Le Gouill, Nöel Milpied, Agnès Buzyn, Journal of Clinical Oncology	2008	291
Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies Gandhi Damaj, Alain Duhamel, Marie Robin, Journal of Clinical Oncology	2012	204
Diagnosis of Toxoplasmosis after Allogeneic Stem Cell Transplantation: Results of DNA Detection and Serological Techniques Hélène Fricker‐Hidalgo, Claude‐Eric Bulabois, Marie‐Pierre Brenier‐Pinchart, Clinical Infectious Diseases	2008	121
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study Pau Montesinos, Gail J. Roboz, Claude‐Eric Bulabois, Leukemia Hematological MalignancyMedicineAcute Myeloid LeukemiaPharmacologyPharmacotherapy	2020	96
Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B Cell Lymphoma: Report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire Anne Sîrvent, Nathalie Dhédin, Mauricette Michallet, Biology of Blood and Marrow Transplantation Cell TherapyLow Nonrelapse MortalityImmunologyPathologyImmunotherapy	2009	93
Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience Steven Le Gouill, Nicolaus Kröger, Nathalie Dhédin, Annals of Oncology Cell TherapyTransplantationMarrow TransplantationStem Cell TransplantationImmunology	2012	78
Use of Real-Time PCR To Process the First Galactomannan-Positive Serum Sample in Diagnosing Invasive Aspergillosis Laurence Millon, Renaud Piarroux, Éric Deconinck, Journal of Clinical Microbiology	2005	71
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors Éolia Brissot, Myriam Labopin, Jan J. Cornelissen, Journal of Hematology & Oncology	2020	67
Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels Elodie Gautier‐Veyret, Xavier Fonrose, Julia Tonini, Antimicrobial Agents and Chemotherapy Trough ConcentrationsTransplantation MedicinePharmacotherapyLaboratory HematologyAbstract Voriconazole	2015	64

Page 1